Early-stage cancer diagnostics company Clyz Labs backed by Catapult Ventures

clyz .jpg

An initiative managed by Catapult Ventures has backed an early-stage cancer diagnostics company.

CLYZ Labs – which is based on Alderley Park – was founded in 2017. It is developing the Cancertain Assay as a service designed to select the best drug therapy for personalised cancer treatment.

The company will combine information on drug sensitivity of the patient's own tumour cells using 3D techniques along with biomarker and treatment guidelines to provide a recommendation. This is expected to increase life expectancy and reduce costs.

CLYZ Labs' first clinical trial involving its Cancertain test has secured all regulatory approvals following a seed investment from the GM&C Life Sciences Fund. Premier Corporate Finance supported the business in preparation for the fundraising.

Dr Gareth King, life science partner at Catapult Ventures, said: "Highly personalised cancer therapy is fast becoming the standard of care and I've been very impressed with the focus of CLYZ Labs team on improving outcomes for patients with cancer.

"CLYZ Labs is well positioned to provide a fully integrated service to support clinicians to provide the best treatment and care for patients. I look forward to the successful conclusion of this clinical trial."

Dr Himanshu Kataria, director of CLYZ Labs, added: "Lung cancer remains a major health problem with about 65 per cent of patients dying within one year of diagnosis.

"We look forward to continue to work with the GM&C Life Sciences Fund and other investors to bring Cancertain Assay to every lung cancer patient in future."

Katie Droogan